Press Releases on October 9, 2016

topseos.com Reports SEO Brand as the Top Search Engine Optimization Company for the Month of October 2016

NAPLES, FL--(Marketwired - October 09, 2016) - topseos.com, the independent authority on internet marketing, has named SEO Brand the best search engine optimization service for October 2016. Each month the independent research team at topseos.com examines …

topseos.com Reveals SEOP as the Best Digital Marketing Company for the Month of October 2016

NAPLES, FL--(Marketwired - October 09, 2016) - The independent authority on online marketing, topseos.com, has named SEOP the best digital marketing service for October 2016. SEOP was selected due to their remarkable performance in the rigorous evaluation …

Two Major Studies to Be Presented at ESMO 2016 Congress Presidential Symposium Demonstrate Potential of Merck’s KEYTRUDA® (...

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced results from two major studies of KEYTRUDA® (pembrolizumab), the company’s anti-PD-1 therapy, in the first-line treatment of patients …

KEYTRUDA® (pembrolizumab) Showed Continued Overall Survival Benefit Compared to Chemotherapy with Longer Follow-Up in Patients ...

KENILWORTH, N.J.--(BUSINESS WIRE)-- Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that KEYTRUDA® (pembrolizumab), the company’s anti-PD-1 therapy, demonstrated superiority in overall survival (OS) at 18 months …

Two Major Studies to Be Presented at ESMO 2016 Congress Presidential Symposium Demonstrate Potential of Merck’s KEYTRUDA® (...

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced results from two major studies of KEYTRUDA® (pembrolizumab), the company’s anti-PD-1 therapy, in the first-line treatment of patients …

KEYTRUDA® (pembrolizumab) Showed Continued Overall Survival Benefit Compared to Chemotherapy with Longer Follow-Up in Patients ...

KENILWORTH, N.J.--(BUSINESS WIRE)-- Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that KEYTRUDA® (pembrolizumab), the company’s anti-PD-1 therapy, demonstrated superiority in overall survival (OS) at 18 months …

Six-hour run: Porsche donates EUR 180,000 to social initiatives